A therapy that accelerates IAP cleavage would be designed to reverse a qualitatively distinct pathophysiologic effect of hyperglycemia and thus should allow normal maintenance of IGF-I signaling in vascular cells. The gene discussed is CD47; the disease is Hyperglycemia.